Table 4 Bivariate and multivariable Cox regression analysis for predictors of initial HAART regimen change among adult HIV positive patients at University of Gondar Referral Hospital, January 2010 to June, 2015 (n = 410)
Variable | Survival status | Crude HR (95 % CI) | Adjusted HR (95 % CI) | |
|---|---|---|---|---|
Event | Censored | |||
Weight | ||||
<60 kg | 56 | 262 | 1.00 | 1.00 |
≥60 kg | 32 | 60 | 1.91 (1.24–2.95) | 1.19 (0.70–2.03) |
Baseline WHO stage | ||||
Stage I/II | 23 | 155 | 1.00 | 1.00 |
Stage III | 50 | 122 | 2.45 (1.49–4.01) | 1.92 (1.12–3.31)* |
Stage IV | 15 | 43 | 1.945 (1.01–3.73) | 0.55 (0.25–1.18) |
TB on initial regimen | ||||
Yes | 20 | 6 | 7.92 (4.76–13.16) | 8.33 (4.47–15.53)* |
No | 68 | 316 | 1.00 | 1.00 |
Initial NRTI backbone | ||||
TDF/ABC | 26 | 151 | 1.00 | 1.00 |
AZT/D4T | 62 | 171 | 1.68 (1.06–2.65) | 072 (0.40–1.28) |
Initial NNRTI | ||||
NVP | 60 | 161 | 1.84 (1.17–2.88) | 1.74 (0.79–3.84) |
EFV | 28 | 161 | 1.00 | 1.00 |
Co-medication with ART other than CPT | ||||
Yes | 32 | 52 | 2.68 (1.74–4.15) | 2.54 (1.46–4.39)* |
No | 56 | 270 | 1.00 | 1.00 |
Side effect | ||||
Yes | 63 | 9 | 18.93 (11.82–30.29) | 25.27 (15.12–42)* |
No | 25 | 313 | 1.00 | 1.00 |